48 assets in Gliosarcoma

Therapeutic assets addressing Gliosarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cediranib Gliosarcoma	Northwestern University	P2	BBB (76)
Irinotecan Gliosarcoma	RTOG Foundation, Inc.	P3	BB (68)
Vorinostat Gliosarcoma	National Cancer Institute (NCI)	P2	BB (68)
Cyclophosphamide Gliosarcoma	Mayo Clinic	P2	BB (67)
(+)-Vincristine Gliosarcoma	RTOG Foundation, Inc.	P3	BB (67)
Ipilimumab Gliosarcoma	University College, London	P2/3	BB (64)
Nivolumab Gliosarcoma	Andrew P. Groves	P2/3	BB (64)
Carboplatin Gliosarcoma	Northwestern University	P2	B (63)
Nivestim Gliosarcoma	Leland Metheny	P2	B (63)
Gm-Csf Gliosarcoma	Epitopoietic Research Corporation	P3	B (62)
Lomustine Gliosarcoma	NRG Oncology	P3	B (62)
Pembrolizumab Gliosarcoma	Mayo Clinic	P2	B (60)
Veliparib Gliosarcoma	National Cancer Institute (NCI)	P2/3	B (60)
o6-benzylguanine Gliosarcoma	Leland Metheny	P2	B (59)
Camustine Gliosarcoma	Leland Metheny	P2	B (58)
Sargramostim Gliosarcoma	Roswell Park Cancer Institute	P2	B (58)
Adriamycin Gliosarcoma	Northwestern University	P2	CCC (53)
Balstilimab Gliosarcoma	Northwestern University	P2	CCC (53)
Botensilimab Gliosarcoma	Northwestern University	P2	CCC (53)
Cabozantinib Gliosarcoma	M.D. Anderson Cancer Center	P1/2	CCC (53)
erc1671 Gliosarcoma	Epitopoietic Research Corporation	P2	CCC (53)
Montanide Isa 51 Gliosarcoma	Roswell Park Cancer Institute	P2	CCC (53)
Survaxm Gliosarcoma	Roswell Park Cancer Institute	P2	CCC (53)
Efineptakin Alfa Gliosarcoma	Mayo Clinic	P2	CCC (49)
Atezolizumab Gliosarcoma	M.D. Anderson Cancer Center	P1/2	CCC (48)
m032 Gliosarcoma	University of Alabama at Birmingham	P1/2	CC (45)
Lonafarnib Gliosarcoma	Duke University	P1	CC (44)
Azacitidine Gliosarcoma	Andrew P. Groves	P1	CC (43)
c134 Gliosarcoma	James Markert, MD	P1	CC (43)
Carboxylesterase-Expressing Allogeneic Neural Stem Cells Gliosarcoma	City of Hope Medical Center	P1	CC (43)
Cord Blood-Derived Expanded Allogeneic Natural Killer Cells Gliosarcoma	M.D. Anderson Cancer Center	P1	CC (43)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Gliosarcoma	National Cancer Institute (NCI)	P1	CC (43)
Onc 206 Gliosarcoma	Jazz Pharmaceuticals	P1	CC (43)
Oncolytic Adenovirus Ad5-Dnx-2401 Gliosarcoma	M.D. Anderson Cancer Center	P1	CC (43)
Photochemotherapy Using 3-Ethyl-3-Deacetyl-Bacteriopurpurin-18-N-Butylimide Methyl Ester Gliosarcoma	Photolitec LLC	P1	CC (43)
Abbv-637 Gliosarcoma	Memorial Sloan Kettering Cancer Center	P1	CC (41)
Abexinostat Gliosarcoma	University of Nebraska	P1	CC (41)
Chloroquine Gliosarcoma	Barbara Ann Karmanos Cancer Institute	P1	CC (41)
Eras-801 Gliosarcoma	Memorial Sloan Kettering Cancer Center	P1	CC (41)
Mirzotamab Clezutoclax Gliosarcoma	Memorial Sloan Kettering Cancer Center	P1	CC (41)
Olanzapine Gliosarcoma	National Cancer Institute (NCI)	P1	CC (41)
Selinexor Gliosarcoma	National Cancer Institute (NCI)	P1	CC (41)
S-Gboxin Gliosarcoma	Petrov, Andrey	P1	CC (41)
Liothyronine Gliosarcoma	Emory University	Early P1	C (39)
Methimazole Gliosarcoma	Emory University	Early P1	C (38)
Progesterone Gliosarcoma	Emory University	Early P1	C (38)
gi-102 Gliosarcoma	Mayo Clinic	P2	NR ()
p140k-mgmt Gliosarcoma	Leland Metheny	P2	NR ()